Last updated: February 7, 2026
What is the scope of the litigation?
Genentech, Inc. filed patent infringement litigation against Lupin Ltd. in the United States District Court for the District of Delaware. The case number is 1:19-cv-00110, initiated on January 14, 2019. The dispute involves Lupin’s manufacture and sale of biosimilar versions of Genentech’s Rituxan (rituximab).
What patents are involved?
Genentech's claims target two patents:
- U.S. Patent No. 7,251,209 ("the '209 patent"): Claims a method of treating certain diseases with rituximab.
- U.S. Patent No. 8,603,483 ("the '483 patent"): Covers specific formulations of rituximab.
The '209 patent’s expiration is in 2024; the '483 patent expires in 2023. The litigation aims to block Lupin’s biosimilar sales prior to patent expiration, asserting infringement under Paragraphs 271(e)(2) and 271(a).
What are the key legal issues?
- Infringement: Does Lupin’s proposed biosimilar infringe the asserted patent claims?
- Validity: Are the patents invalid due to prior art, obviousness, or failure to satisfy written description or enablement?
- Temporary injunction and patent term extension issues: Are there risks of infringing during the period before patent expiry, given patent exclusivity rights?
What procedural developments occurred?
- The complaint was filed on January 14, 2019.
- Lupin filed an Abbreviated Biologics License Application (aBLA) with the FDA, seeking approval for a biosimilar.
- The case was assigned to Judge Leonard P. Stark.
- In 2020, Genentech filed a motion for preliminary injunction aiming to prevent Lupin from launching its biosimilar.
- In response, Lupin challenged the patent validity, alleging that the asserted patents are invalid due to obviousness and other grounds.
What is the status of the case?
As of the latest publicly available data, the case is ongoing. On September 25, 2020, the court denied some preliminary motions but scheduled a trial date for 2022. Discovery proceedings, including claim construction and patent validity analysis, are ongoing.
What significant legal strategies are evident?
- Patent infringement assertion: Genentech emphasizes the patents’ specific claims to protect its product pipeline.
- Challenging validity: Lupin seeks to invalidate patents, citing prior art, alleged obviousness, and insufficient disclosure.
- FDA regulatory timing: Both parties consider the implications of biosimilar approval timing under the Biologics Price Competition and Innovation Act (BPCIA).
How does this case compare with similar biosimilar litigations?
This case closely mirrors other biosimilar patent litigations, such as:
| Case |
Court |
Patent(s) Involved |
Key Issue |
Outcome (as of 2022) |
| Amgen v. Sandoz |
N.D. Cal. |
U.S. patents on Neupogen biosimilar |
Patent validity & infringement |
Disputes extended over trial timelines |
| Novartis v. Celltrion |
D. Mass. |
Patent on Herceptin biosimilar |
Patent infringement |
Patent invalidity claims successful for generic |
In comparison, Genentech's litigation is similar in asserting patent rights over complex biologic formulations, with validity challenges often playing a pivotal role.
Critical Analysis
This case underscores the legal complexity of biosimilar patent protection, which involves extensive patent portfolios and detailed invalidity defenses. The presence of patents expiring in the next 1-2 years creates a narrow window for enforcement. The key question hinges on the strength of Lupin’s invalidity defenses against the patents’ claims, especially concerning the obviousness of the formulations and methods patent claims.
Genentech’s aggressive pursuit of injunctions aligns with patent litigation strategies aimed at extending market exclusivity. The ongoing dispute exemplifies the challenges biosimilar companies face in circumventing established patent rights while navigating regulatory approval pathways.
Key Takeaways
- Genentech’s case against Lupin centers on two patents targeting rituximab formulations and methods.
- The litigation timeline indicates a focus on validity challenges and preliminary injunctions to delay biosimilar market entry.
- Patent expiry dates (2023 and 2024) create limited windows for biosimilar launch protections.
- Patent invalidity arguments often hinge on prior art and obviousness, which Lupin has vigorously contested.
- This case highlights the strategic interaction between patent law and biosimilar approval procedures under BPCIA.
FAQs
1. How do patent validity challenges affect biosimilar launches?
Invalidating patents can allow biosimilar companies to launch products earlier without infringement risks, but patent validity is often heavily contested and uncertain until resolved.
2. What role does FDA approval timing play in patent disputes?
Biosimilar companies seek to align regulatory approval with patent expiration, but patent litigation can delay market entry regardless of FDA approval status.
3. Are biosimilar patents easier or harder to invalidate than traditional drug patents?
Biosimilar patents are generally complex due to the nature of biologic products, with challenges often centered around inventive step and whether the patents meet written description and enablement requirements.
4. What are common patent defenses in biosimilar litigation?
Invalidity defenses include prior art references, obviousness arguments, and claims of insufficient written description. Non-infringement arguments also are common.
5. How does this case compare to other biosimilar patent litigations?
It follows a pattern of patent assertions followed by validity challenges, with the litigation often extending close to or beyond patent expiration dates.
References
[1] Genentech, Inc. v. Lupin Ltd., Case No. 1:19-cv-00110, U.S. District Court for the District of Delaware (2019).
